Video

Dr. Lieu on Investigational Immunotherapy Strategies in mCRC

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associate director for clinical research, at the University of Colorado Cancer Center, discusses investigational immunotherapy strategies in metastatic colorectal cancer (mCRC).

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associate director for clinical research, at the University of Colorado Cancer Center, discusses investigational immunotherapy strategies in metastatic colorectal cancer (mCRC).

The phase III IMblaze370 trial tested the combination of the MEK inhibitor cobimetinib (Cotellic) and the PD-L1 inhibitor atezolizumab (Tecentriq), versus atezolizumab alone or regorafenib (Stivarga) alone in the third-line setting. However, the trial was negative; there was no arm that did statistically significantly better than the others, says Lieu. Notably, the combination of cobimetinib and atezolizumab was not shown to be superior to regorafenib, which is the current standard of care.

An ongoing phase II trial at the University of Colorado is testing a similar strategy with MEK and PD-1 inhibition. In the trial, investigators are looking at the combination of the MEK inhibitor binimetinib (Mektovi), the VEGF inhibitor bevacizumab (Avastin), and the PD-1 inhibitor pembrolizumab (Keytruda) in patients with microsatellite stable CRC. Because this trial is still accruing, investigators will have to wait some time before the results are revealed.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity